Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Revenue | 142M | 10.2% |
| Gross Profit | 120M | 9.8% |
| Cost of Revenue | 22M | 12.3% |
| Operating expense | 57M | 2% |
| Net Income | 56M | 27.5% |
| EBITDA | 72M | 42% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 851M | 10.3% |
| Total Liabilities | 124M | 11.4% |
| Total Equity | 728M | 10.1% |
| Shares Outstanding | 126M | 0.7% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | 71M | 2.7% |
| Cash from financing | 4.4M | 174.2% |
EPS
Financial Highlights for Catalyst Pharmaceuticals in Q4 '24
Catalyst Pharmaceuticals reported a revenue of 142M, which is a 10.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 120M, marking a 9.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 22M, a 12.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 57M, showing a -2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 56M, showing a 27.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 72M, showing a 42% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Catalyst Pharmaceuticals with growth in revenue, gross profit, and net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
